MedTrace Logo

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

NCT05541367 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-09-15

No results posted yet for this study

Summary

18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs ， to measure residual estrogen receptors during endocrine therapy and to determine biologically optimal doses of novel estrogen receptor-targeted drugs .This study aimes to explore the efficacy of 18F-FES PET/CT in evaluating the expression levels of ER in primary and metastatic breast cancer patients.

Conditions

  • Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • Estrogen-receptor-negative Breast Cancer

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • ZHU XIAOHUA, DR · Tongji Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05541367 on ClinicalTrials.gov